Sanofi has finalized its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to its portfolio. The $15.50 per share deal strengthens Sanofi’s position in adult immunization.
The merger of Auro Vaccines and Curateq Biologics, a part of Aurobindo Pharma, was approved today during a board meeting of the company held.
.png)
Eli Lilly has agreed to acquire Orna Therapeutics in a deal valued at up to $2.4 billion, strengthening its position in in vivo CAR-T therapies and expanding options for patients with B cell-driven autoimmune diseases.
Alembic Pharmaceuticals has secured USFDA approval for its generic Carbidopa, Levodopa, and Entacapone tablets.
Gland Pharma’s Zoledronic Acid Injection, a treatment for malignancy-related bone issues, has received USFDA approval. This abbreviated new drug application (ANDA) approval enhances Gland Pharma's presence in the injectable market.
Cipla Limited has announced their “Win Over Weight” campaign on a national scale to create a new impression of obesity in India.
The CDSCO has issued a draft guidance document to help IVD medical device importers file import license applications online through the CDSCO portal and the National Single Window System, aiming to ensure faster and accurate approvals.
.png)
AstraZeneca and Daiichi Sankyo’s Datroway has received FDA Priority Review for unresectable or metastatic triple-negative breast cancer patients who are not eligible for immunotherapy, marking a key regulatory milestone.
AstraZeneca’s subcutaneous Saphnelo application rejected by FDA, delaying approval until 2026. However, it remains approved in the EU for treating lupus patients.
.png)
Novo Nordisk said today that its next-generation obesity drug CagriSema delivered better weight loss and blood sugar control than Wegovy in a late-stage diabetes trial, strengthening its pipeline in the fast-growing market.
, CDSCO.jpg)